| 摘要 |
The invention relates to an in vitro method of detecting or monitoring the liver specific transcriptional activity or pharmacological activation of FXR in a human being or mammal, comprising quantifying the expression level of histidine-rich glycoprotein in the human being or mammal. The invention also relates to histidine-rich glycoprotein as a biomarker for monitoring FXR pharmacodynamic responsiveness of a human being or mammal to a FXR activity modulator. Furthermore, the invention relates to the use of histidine-rich glycoprotein for detecting or monitoring liver specific FXR activation in a human being or mammal. |
